Market Place
Sourcing Support
Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease
29 Jul 2024 //
BUSINESSWIRE
EMA Accepts Novaliq’s MAA for CyclASol for the Treatment of Dry Eye Disease
24 Aug 2023 //
BUSINESSWIRE
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE from Novaliq
18 Jul 2023 //
BUSINESSWIRE
Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03
13 Jun 2023 //
BUSINESSWIRE
Novaliq Announces FDA Approval of VEVYE 0.1% for Treatment of Dry Eye Disease
08 Jun 2023 //
BUSINESSWIRE
Bausch + Lomb and Novaliq win approval for dry eye disease treatment
19 May 2023 //
ENDPTS
Novaliq Announces Presentation of New Scientific Data on Cyclosporine
02 May 2023 //
BUSINESSWIRE
Novaliq Announces Publication of Second Pivotal PIII Trial Data on CyclASol 0.1%
12 Apr 2023 //
BUSINESSWIRE
Novaliq Plans to File Markting Authorisation Application for CyclASol in E.U.
08 Feb 2023 //
BUSINESSWIRE
Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03
04 Jan 2023 //
BUSINESSWIRE
Novaliq Announces FDA Acceptance of the New Drug Application for CyclASol
24 Oct 2022 //
BUSINESSWIRE
Bausch + Lomb & Novaliq Announce USFDA Filing Acceptance for Investig. NOV03
06 Sep 2022 //
PRNEWSWIRE
Bausch + Lomb and Novaliq Submit NDA for Investigational Treatment NOV03
07 Jul 2022 //
PRNEWSWIRE
Novaliq Spin off Dermaliq Emerges with $15M Series A
20 Jan 2022 //
TRIALSITENEWS
Dermaliq Tx Signs $15M Series A Round to Advance Drug Therapies into Trials
18 Jan 2022 //
PRNEWSWIRE
Novaliq Announces POSITIVE Topline Results for SECOND PHASE 3 TRIAL of CyclASol
21 Dec 2021 //
PRNEWSWIRE
PHASE 3 OF SHR8058 EYE DROPS SHOWS STATISTICALLY SIGNIFICANT TOPLINE RESULTS
15 Dec 2021 //
PRNEWSWIRE
Novaliq Receives EU Quality Management Certificate as per MDR
12 Oct 2021 //
PRNEWSWIRE
Aerie brushes off dry eye trial failure
16 Sep 2021 //
EVALUATE
Novaliq Completes Enrollment of Second Ph3 Study for CyclASol
10 Aug 2021 //
OPHTHALMOLOGYTIMES
Novaliq Completes Enrollment of Second Ph3 Study for CyclASol
10 Aug 2021 //
OPHTHALMOLOGYTIMES
Novaliq Announces More than 50% Patients Enrolled in CyclASol® Phase 3
28 Apr 2021 //
PRNEWSWIRE
Novaliq Announces More than 50% Patients in CyclASol® Ph3 Dry Eye Disease
28 Apr 2021 //
PRNEWSWIRE
Novaliq First Patient Randomized in the Phase 3 trial ESSENCE-2 of CyclASol®
08 Dec 2020 //
PRNEWSWIRE
Novaliq Announces First Patient in the Ph3 trial ESSENCE-2 of CyclASol®
08 Dec 2020 //
PRNEWSWIRE
Novaliq Raises New Capital to Accelerate the Commercialization of its Lead Products for Dry Eye Disease
11 Oct 2018 //
BUSINESSWIRE
Novaliq’s NovaTears®+Omega-3 Approved in EU - Enhanced Treatment Dry Eye Disease
06 Dec 2017 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.